Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina
- PMID: 17075335
- DOI: 10.1097/01.qco.0000247592.21295.a5
Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina
Abstract
Purpose of review: The aim of this review is to describe knowledge, mainly of the last 15 years, that changed criteria for specific treatment against Trypanosoma cruzi infection.
Recent findings: Over the past 15 years, there has been an increase in the use of new methodologies to evaluate the efficacy of antiparasitic treatments. These tools showed that the evaluation period for trypanocidal treatment effectiveness could be shortened. Based on the hypothesis that Chagas' cardiomyopathy may indeed be triggered by persistent parasitic infection, it seems plausible that trypanocidal therapy may delay, reduce or prevent the progression to the disease.
Summary: Based on the present knowledge, we can assume that every patient infected with Trypanosoma cruzi in the acute phase and in the early chronic phase (i.e. children under 16 years old) must be treated, and adults could be treated. In this area, research priorities should target obtaining new drugs to allow shorter treatments with fewer adverse reactions and improving new tools to confirm cure when patients are treated during the Chronic Phase.
Similar articles
-
[Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina].Medicina (B Aires). 1999;59 Suppl 2:166-70. Medicina (B Aires). 1999. PMID: 10668259 Review. Spanish.
-
[The chemotherapy of Chagas disease].Medicina (B Aires). 1999;59 Suppl 2:147-65. Medicina (B Aires). 1999. PMID: 10668258 Review. Spanish.
-
Long term evaluation of etiological treatment of chagas disease with benznidazole.Rev Inst Med Trop Sao Paulo. 2002 Jan-Feb;44(1):29-37. Rev Inst Med Trop Sao Paulo. 2002. PMID: 11896410 Clinical Trial.
-
Trypanocidal drugs: mechanisms, resistance and new targets.Expert Rev Mol Med. 2009 Oct 29;11:e31. doi: 10.1017/S1462399409001252. Expert Rev Mol Med. 2009. PMID: 19863838 Review.
-
[Update on the treatment of Chagas' disease].Rev Med Chil. 2011 Feb;139(2):247-57. Epub 2011 Jul 11. Rev Med Chil. 2011. PMID: 21773664 Review. Spanish.
Cited by
-
Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi In Vitro and In Vivo.Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0028422. doi: 10.1128/aac.00284-22. Epub 2022 Oct 31. Antimicrob Agents Chemother. 2022. PMID: 36314800 Free PMC article.
-
The translational challenge in Chagas disease drug development.Mem Inst Oswaldo Cruz. 2022 May 23;117:e200501. doi: 10.1590/0074-02760200501. eCollection 2022. Mem Inst Oswaldo Cruz. 2022. PMID: 35613156 Free PMC article. Review.
-
Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ.Front Immunol. 2021 Dec 2;12:782891. doi: 10.3389/fimmu.2021.782891. eCollection 2021. Front Immunol. 2021. PMID: 34925364 Free PMC article.
-
WHF IASC Roadmap on Chagas Disease.Glob Heart. 2020 Mar 30;15(1):26. doi: 10.5334/gh.484. Glob Heart. 2020. PMID: 32489799 Free PMC article. Review.
-
Longitudinal follow up of serological response in children treated for Chagas disease.PLoS Negl Trop Dis. 2019 Aug 29;13(8):e0007668. doi: 10.1371/journal.pntd.0007668. eCollection 2019 Aug. PLoS Negl Trop Dis. 2019. PMID: 31465522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
